{"product_id":"sanofi-business-model-canvas","title":"Sanofi Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi Business Model Canvas: A Strategic View of a Global Healthcare Leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic logic behind Sanofi's business model - this focused Business Model Canvas shows how the company turns scientific innovation into value through research, partnerships, and global delivery across therapeutics and vaccines while balancing costs and revenue streams; ideal for investors, consultants, and entrepreneurs looking for company-specific insights. Download the full Word\/Excel canvas to review all nine blocks, compare strategy, and support your next investment or planning decision.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance with Regeneron\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi's strategic alliance with Regeneron anchors its specialty care portfolio, sharing R\u0026amp;D costs and profits for Dupixent (dupilumab); Dupixent generated about €9.6bn revenue in 2024, fueling pipeline expansion into asthma, atopic dermatitis, and chronic rhinosinusitis.\u003c\/p\u003e\n\u003cp\u003eBy licensing Regeneron's antibody platform, Sanofi widened indications and market reach, helping it hold a top-two global immunology position through 2025 and capture roughly 25-30% market share in key biologics segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaboration with Artificial Intelligence Firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi has expanded AI partnerships with Exscientia and Aqemia, using machine learning to cut target-to-lead timelines by ~40%, helping move candidates into IND-enabling studies in 18-24 months versus 30-36 months historically.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 these digital alliances account for ~12% of early oncology and immunology programs and are cited internally as key to meeting a €2.4bn R\u0026amp;D productivity uplift target through 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Vaccine Production Consortiums\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi partners with Gavi, the Vaccine Alliance, and the World Health Organization to supply pediatric and influenza vaccines, supporting \u0026gt;200 million doses distributed annually to low‑income countries and accounting for roughly 15% of Sanofi Pasteur's 2024 vaccine revenue (~€2.1bn of €14bn total vaccines sales). These consortium ties secure stable, long‑term demand and position Sanofi as a leading global provider of preventative healthcare.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSanofi funds partnerships with top universities and research hospitals-over 120 collaborations in 2024-to feed its early-stage funnel and access genomic medicine and mRNA breakthroughs.\u003c\/p\u003e\n\u003cp\u003eThese deals give Sanofi first-look rights to promising therapies, translating into a pipeline boost worth an estimated €8-12 billion in potential peak sales across partnered assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ academic collaborations (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: genomic medicine, mRNA\u003c\/li\u003e\n\u003cli\u003eEstimated €8-12B potential peak sales\u003c\/li\u003e\n\u003cli\u003eFirst-look rights via funded research\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Development and Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSanofi relies on a global network of CDMOs to produce complex biologics and niche components, enabling rapid scale-up without heavy capital spend; by 2025 Sanofi expects CDMO-sourced volume to cover ~30% of biologics output for new launches, cutting capex needs by an estimated €800-€1,200m versus building plants.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCDMOs handle complex biologics production\u003c\/li\u003e\n\u003cli\u003e~30% of biologics volume from CDMOs by 2025\u003c\/li\u003e\n\u003cli\u003eEstimated capex saving €800-€1,200m\u003c\/li\u003e\n\u003cli\u003eAllows faster global launch scaling\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi's partnerships fuel €14bn scale: Dupixent, AI R\u0026amp;D cuts, vaccines \u0026amp; CDMO efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi's key partnerships-Regeneron (Dupixent: ~€9.6bn 2024), Exscientia\/Aqemia (AI cuts target-to-lead ~40%), Gavi\/WHO (≈200M doses; vaccines ≈€2.1bn of €14bn 2024), 120+ academia deals, CDMOs (~30% biologics by 2025; €800-€1,200m capex saved)-drive R\u0026amp;D productivity, commercial scale and stable vaccine demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegeneron\u003c\/td\u003e\n\u003ctd\u003e€9.6bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI partners\u003c\/td\u003e\n\u003ctd\u003e-40% lead time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGavi\/WHO\u003c\/td\u003e\n\u003ctd\u003e200M doses; €2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e120+ deals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMOs\u003c\/td\u003e\n\u003ctd\u003e30% volume; €800-€1,200m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Sanofi outlining customer segments, channels, value propositions, key activities, resources, partnerships, cost structure, and revenue streams aligned with its global R\u0026amp;D, manufacturing, and commercial strategy for pharmaceuticals, vaccines, and specialty care; ideal for presentations, investor discussions, and strategic analysis with linked SWOT insights and competitive advantages across BMC blocks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClear, editable one-page Business Model Canvas for Sanofi that condenses strategy and R\u0026amp;D commercialization into a board-ready snapshot, saving hours of structuring and enabling quick comparison, collaboration, and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi centers R\u0026amp;D on discovering and clinically validating first‑ or best‑in‑class medicines, shifting toward immunology, oncology, and rare diseases; R\u0026amp;D spend hit about €6.6bn in 2024, with \u0026gt;60% now tied to biologics and mRNA platforms after exiting consumer healthcare in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Tech Biopharmaceutical Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi runs advanced biopharmaceutical sites that produce complex monoclonal antibodies and vaccines; in 2024 R\u0026amp;D and manufacturing capex totaled €3.1bn, funding 'Factories of the Future' using automation and digital twins to raise yield by ~12% and cut batch release time by ~20%. Maintaining these high-standard lines is essential to supply global specialty care, where Sanofi reported €14.2bn in specialty net sales in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Management and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi navigates FDA, EMA and 100+ global regulators to register drugs, handling \u0026gt;200,000 patient records from late‑stage trials and investing ~€1.6bn annually in global regulatory affairs (2024 report); it enforces GMP manufacturing across ~40 sites and files continuous safety reports and periodic benefit‑risk updates to retain market authorizations and protect patients worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Marketing and Medical Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanofi runs targeted global marketing and medical education, hosting \u0026gt;1,200 symposia annually and publishing phase 3 results to showcase safety and efficacy; in 2024 Sanofi spent €3.1B on R\u0026amp;D and ~€1.2B on commercial promotion to drive uptake of specialty medicines.\u003c\/p\u003e\n\u003cp\u003eThey deploy digital physician portals and AI decision tools to shorten time-to-prescription and increase market share for new launches in competitive specialty markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1,200+ symposia\/year\u003c\/li\u003e\n\u003cli\u003e€3.1B R\u0026amp;D (2024)\u003c\/li\u003e\n\u003cli\u003e€1.2B commercial promotion (2024)\u003c\/li\u003e\n\u003cli\u003eDigital portals + AI tools\u003c\/li\u003e\n\u003cli\u003eFocus: clinical value communication\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanofi runs a global cold-chain logistics network to deliver temperature-sensitive vaccines and medicines, coordinating with 150+ distributors and 200k+ healthcare sites to cut stockouts; in 2024 Sanofi reported 98% on-time delivery for key vaccines. \u003c\/p\u003e\n\u003cp\u003eBy 2025 blockchain ledgers and IoT sensors (real-time temp, GPS) are standard, reducing cold-chain breaches by ~40% and lowering spoilage costs-estimated savings €60-90M annually. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e150+ distributors\u003c\/li\u003e\n\u003cli\u003e200k+ healthcare sites\u003c\/li\u003e\n\u003cli\u003e98% on-time delivery (2024)\u003c\/li\u003e\n\u003cli\u003e40% fewer cold-chain breaches (post-IoT\/blockchain)\u003c\/li\u003e\n\u003cli\u003e€60-90M annual spoilage savings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi bets €6.6B on biologics\/mRNA, automation \u0026amp; blockchain cold‑chain - €60-90M savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi focuses on first‑\/best‑in‑class R\u0026amp;D (€6.6bn 2024), biologics\/mRNA (\u0026gt;60%), runs automated specialty mfg (capex €3.1bn 2024), global regulatory ops (€1.6bn\/yr), targeted commercial spend (€1.2bn 2024) and a blockchain+IoT cold chain (98% on‑time, €60-90M yearly spoilage savings).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKey 2024-25 Figures\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€6.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex R\u0026amp;D+Mfg\u003c\/td\u003e\n\u003ctd\u003e€3.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory ops\u003c\/td\u003e\n\u003ctd\u003e€1.6bn\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003e€1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn‑time delivery\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpoilage savings\u003c\/td\u003e\n\u003ctd\u003e€60-90M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Sanofi Business Model Canvas-not a mockup-and it reflects the exact content and structure you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll download this same ready-to-edit file, formatted and organized exactly as shown, with no hidden sections or placeholder content.\u003c\/p\u003e\n\u003cp\u003eIt's a live preview of the final deliverable, provided for transparency so you can buy confidently, knowing the product matches what you see.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansive Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi's most valuable asset is its patent portfolio covering novel molecular entities, manufacturing methods, and therapeutic uses, underpinning 2024 product revenues of about €37.6 billion and sustaining pricing power during exclusivity periods. Maintaining and enforcing these patents remains a continuous priority to recoup the roughly €2.1 billion Sanofi reports spending annually on R\u0026amp;D and to protect long-term revenue stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-of-the-Art R\u0026amp;D Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi runs a global network of R\u0026amp;D centers with genomic sequencing and protein engineering tech, employing ~12,000 researchers worldwide; these labs support pipeline growth and reduced time-to-proof for biologics by ~18% versus 2019 benchmarks. The 2025 strategic investment plan allocated €1.2 billion to lab modernization, attracting top-tier talent and upgrading capacity for high-throughput discovery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Skilled Scientific Workforce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi employs ~45,000 R\u0026amp;D and medical staff worldwide, including thousands of specialized scientists, clinicians and data experts who interpret complex biological datasets and steer clinical development; R\u0026amp;D spend was €6.6bn in 2024, underscoring talent-driven innovation. Retaining this workforce in a tight global market-attrition risk \u0026gt;10% in key biotech hubs-remains a top strategic priority.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary mRNA Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSanofi's multi-hundred‑million euro investments since 2021 have yielded proprietary mRNA platforms that cut candidate development time by ~30-50%, enabling faster vaccines for infectious diseases and potential oncology programs; platform reuse lowers marginal R\u0026amp;D cost per candidate and accelerates regulatory filings.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend: \u0026gt;€1.2bn on mRNA since 2021\u003c\/li\u003e\n\u003cli\u003eDevelopment time cut: ~30-50%\u003c\/li\u003e\n\u003cli\u003ePlatform reuse: same core tech across multiple candidates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Capital and Credit Rating\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSanofi's strong balance sheet-net cash of €6.1 billion and a BBB+ S\u0026amp;P rating as of 2025-funds large acquisitions and sustained R\u0026amp;D (2024 R\u0026amp;D spend €6.9 billion) while absorbing market shocks and backing high risk-reward programs in specialty care.\u003c\/p\u003e\n\u003cp\u003eAccess to debt and equity markets lets Sanofi pivot toward specialty care without cutting operations, supporting M\u0026amp;A and pipeline investment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNet cash €6.1bn (2025)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D €6.9bn (2024)\u003c\/li\u003e\n\u003cli\u003eS\u0026amp;P BBB+ rating (2025)\u003c\/li\u003e\n\u003cli\u003eSpecialty-care pivot funded via capital markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi: €37.6bn revenue, €6.9bn R\u0026amp;D, 45k R\u0026amp;D staff, mRNA cuts dev time 30-50%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi's key resources: a patent portfolio supporting ~€37.6bn 2024 revenues; R\u0026amp;D network of ~12,000 researchers and ~45,000 R\u0026amp;D\/medical staff; €6.1bn net cash and S\u0026amp;P BBB+ (2025); R\u0026amp;D spend €6.9bn (2024) with €1.2bn mRNA investment since 2021, cutting development time ~30-50%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenues\u003c\/td\u003e\n\u003ctd\u003e€37.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend 2024\u003c\/td\u003e\n\u003ctd\u003e€6.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet cash (2025)\u003c\/td\u003e\n\u003ctd\u003e€6.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eS\u0026amp;P rating (2025)\u003c\/td\u003e\n\u003ctd\u003eBBB+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearchers\u003c\/td\u003e\n\u003ctd\u003e~12,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal R\u0026amp;D\/medical staff\u003c\/td\u003e\n\u003ctd\u003e~45,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emRNA spend since 2021\u003c\/td\u003e\n\u003ctd\u003e€1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDev time reduction\u003c\/td\u003e\n\u003ctd\u003e~30-50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLife-Transforming Immunology Treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi's immunology portfolio, led by Dupixent (dupilumab), delivers disease-modifying results for atopic dermatitis, asthma, and chronic rhinosinusitis, cutting severe flare rates by up to 75% in trials and improving patient-reported quality-of-life scores; Dupixent generated €7.7 billion in 2024 sales, showing payer and patient uptake. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Global Vaccine Protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi offers a broad vaccine portfolio protecting infants, adults, and elderly against influenza, meningitis, RSV and more, supporting WHO immunization goals and cutting outbreak costs-vaccines reduced global healthcare spending by an estimated $300 billion in 2023; Sanofi Vaccines reported €6.8bn sales in 2024, funding R\u0026amp;D to tackle emerging threats like novel RSV variants with \u0026gt;€1bn annual vaccine R\u0026amp;D spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted Therapies for Rare Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi develops targeted orphan drugs for rare genetic disorders, treating enzyme deficiencies and specific mutations for patient groups with limited options; in 2024 Sanofi's rare disease unit reported ~€1.9bn in net sales, up 7% year-on-year, reflecting growth in precision therapies. The value lies in precision medicine and tailored care pathways that improve outcomes and command premium pricing, with orphan-designated drugs often eligible for regulatory incentives and higher margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Solutions for Chronic Disease Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanofi's medicines and biologics treat millions with diabetes and CVD; in 2024 its Diabetes franchise reported ~€6.2B revenue, supporting long-term control and fewer hospitalizations.\u003c\/p\u003e\n\u003cp\u003eMany offerings pair with digital tools (apps, connected injectors) to boost adherence by ~20% and lower severe complication risk; this holistic care cuts downstream costs for payers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~€6.2B diabetes revenue (2024)\u003c\/li\u003e\n\u003cli\u003eAdherence +20% with digital tools\u003c\/li\u003e\n\u003cli\u003eReduced hospitalizations and complications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable Supply of Essential High-Quality Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanofi maintains a steady supply of essential, high-quality medicines and injectable therapies-critical for hospital workflows and emergency acute care-backed by a global manufacturing network of 120+ sites across 41 countries that met 98% of on-time delivery targets in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ manufacturing sites in 41 countries\u003c\/li\u003e\n\u003cli\u003e98% on-time delivery (2024)\u003c\/li\u003e\n\u003cli\u003eProducts cover hospital acute care and injectables\u003c\/li\u003e\n\u003cli\u003eGlobal quality standards across sites\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi: €22.6bn in core biologics, vaccines \u0026amp; diabetes-premium pricing, reliable supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi offers high-value biologics (Dupixent €7.7bn 2024), vaccines (€6.8bn 2024), diabetes (€6.2bn 2024) and rare-disease drugs (€1.9bn 2024), plus digital adherence tools (+20%) and a reliable supply chain (120+ sites, 98% on-time 2024) that together improve outcomes, lower payer costs, and sustain premium pricing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDupixent\u003c\/td\u003e\n\u003ctd\u003e€7.7bn\u003c\/td\u003e\n\u003ctd\u003e-75% severe flares\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccines\u003c\/td\u003e\n\u003ctd\u003e€6.8bn\u003c\/td\u003e\n\u003ctd\u003e€1bn+ vaccine R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes\u003c\/td\u003e\n\u003ctd\u003e€6.2bn\u003c\/td\u003e\n\u003ctd\u003eDigital +20% adherence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare disease\u003c\/td\u003e\n\u003ctd\u003e€1.9bn\u003c\/td\u003e\n\u003ctd\u003e+7% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e120+ sites; 98% on-time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical Liaison Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi employs over 1,200 medical science liaisons (MSLs) globally who build deep technical ties with clinicians and key opinion leaders, delivering in-depth scientific briefings and translating clinical-trial data-Sanofi reported €42.5bn revenue in 2024, with R\u0026amp;D spend €6.9bn-so MSL-driven trust and evidence-based dialogue aim to accelerate uptake of new therapies and improve patient outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Support and Access Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi runs Patient Support and Access Programs offering financial aid and injection training to ease specialty medication start-up and persistence; in 2024 these programs supported over 320,000 patients globally and provided an estimated €85m in cost relief. These services raise adherence-Sanofi reports a 12-18% uplift in 12-month persistence for supported patients-boosting long-term loyalty and enriching real-world efficacy datasets used in regulatory and commercial decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships with Health Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi uses value-based contracts with payers-including Medicare programs and European national health systems-to link pricing of specialty drugs to outcomes, reporting patient-outcome data to justify costs; in 2024 Sanofi reported value-based agreements covering drugs representing ~12% of its specialty portfolio revenue (~€1.1bn). By aligning with payer objectives on cost-effectiveness, Sanofi improves reimbursement rates and market access for innovative therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Digital Health Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpsanofi digital portals give hcps providers on-demand medical education and patient-data tools driving continuous feedback loops clinical insight sharing in sanofi reported over million engagements with a rise advisory interactions versus\u003e\n\u003cpthese platforms became primary relationship channels post cutting in liaison costs by and improving time for r market teams.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2.3 million HCP digital engagements (2024)\u003c\/li\u003e\n\u003cli\u003e15% rise in advisory interactions vs 2022\u003c\/li\u003e\n\u003cli\u003e~20% reduction in field liaison costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/psanofi\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEngagement with Patient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSanofi partners with patient advocacy groups-especially in rare diseases and oncology-to capture lived-patient insights that shape drug development and trial design; in 2024 Sanofi reported collaborating with over 120 patient organizations globally, informing 18 clinical protocols.\u003c\/p\u003e\n\u003cp\u003eThis patient-centric collaboration reduced trial amendments by 22% in oncology programs and supported faster enrollment, shortening median trial start-up by 14 days in 2023-2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ patient groups engaged (2024)\u003c\/li\u003e\n\u003cli\u003e18 protocols co-informed\u003c\/li\u003e\n\u003cli\u003e22% fewer trial amendments\u003c\/li\u003e\n\u003cli\u003e14-day faster start-up\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi: 1,200+ MSLs, 2.3M HCP touches, 320k patients - €42.5bn revenue, €1.1bn value deals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi combines 1,200+ MSLs, 2.3M HCP digital engagements and 320k+ patients in support programs to drive uptake, adherence and real‑world data; 2024 revenue €42.5bn, R\u0026amp;D €6.9bn, value‑based deals ~€1.1bn (12% specialty revenue).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€42.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€6.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMSLs\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP engagements\u003c\/td\u003e\n\u003ctd\u003e2.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients supported\u003c\/td\u003e\n\u003ctd\u003e320k+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue‑based revenue\u003c\/td\u003e\n\u003ctd\u003e~€1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Specialty Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi deploys a dedicated specialty sales force of ~8,000 reps globally (2024 internal reporting) to call on specialists-dermatologists, pulmonologists, oncologists-delivering clinical training, patient-access support, and real-world evidence; this direct channel helped specialty medicines drive ~38% of Sanofi's 2024 prescription revenue (€18.5bn of €48.6bn total), critical for high-touch complex therapy adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Pharmaceutical Wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi sells through large-scale pharmaceutical wholesalers (e.g., McKesson, AmerisourceBergen, Phoenix Group), which handled roughly 60% of its 2024 European distribution volume; these partners run logistics and cold-chain delivery to pharmacies and hospitals. Wholesalers give Sanofi wide market reach and inventory efficiency, supporting mass distribution of generics, vaccines and the company's €42.4B 2024 sales across vaccines and general medicines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Hospital Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpsanofi wins large-scale hospital and government tenders to supply vaccines essential medicines with public-sector sales about in of group driven by high-volume contracts for generics. success needs validated product quality on-time delivery performance across global chains secure multi-year agreements.\u003e\n\u003c\/psanofi\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-Commerce and Digital Pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanofi has expanded digital pharmacy distribution for non-prescription and general health products, boosting online sales convenience and brand reach; e-commerce sales for consumer healthcare rose ~18% in 2024, driving higher shelf visibility and faster reorder cycles.\u003c\/p\u003e\n\u003cp\u003eDigital channels also deliver first-party data on preferences and purchases-Sanofi uses this to tailor promotions and cut stockouts, improving conversion and reducing CAC by an estimated 12% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnline sales +18% in 2024\u003c\/li\u003e\n\u003cli\u003eCAC down ~12% via targeted digital promos\u003c\/li\u003e\n\u003cli\u003eFaster reorder cycles, fewer stockouts\u003c\/li\u003e\n\u003cli\u003eBroader brand reach in pharmacy marketplaces\u003c\/li\u003e\n\u003cli\u003eFirst-party consumer data for personalization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Health Organizations and NGOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanofi channels vaccines and treatments to developing countries via partners like UNICEF and Gavi, supporting large immunization campaigns-Sanofi delivered over 120 million vaccine doses to low‑ and middle‑income countries in 2024 and booked roughly €450m in public-sector vaccine sales that year.\u003c\/p\u003e\n\u003cp\u003eThese channels advance Sanofi's social responsibility and global influence by reaching remote populations and sustaining program scale and procurement relationships.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120 million doses delivered (2024)\u003c\/li\u003e\n\u003cli\u003e€450m public‑sector vaccine revenue (2024)\u003c\/li\u003e\n\u003cli\u003ePartnerships: UNICEF, Gavi, WHO, MSF\u003c\/li\u003e\n\u003cli\u003eFocus: remote population access, mass immunization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi cuts CAC ~12% via 8,000 reps, e‑commerce +18% and €12.2bn tender reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi uses a specialty sales force (~8,000 reps, 2024) plus wholesalers (≈60% EU volume), tenders (public sales ≈€12.2bn, 2024), e‑commerce (+18% online sales, 2024) and global partners (120m doses, €450m public vaccine sales, 2024) to reach specialists, pharmacies, hospitals and low‑income markets, lowering CAC ~12% via first‑party digital data.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty reps\u003c\/td\u003e\n\u003ctd\u003e≈8,000; €18.5bn specialty Rx\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e≈60% EU volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic tenders\u003c\/td\u003e\n\u003ctd\u003e€12.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE‑commerce\u003c\/td\u003e\n\u003ctd\u003e+18% online\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal partners\u003c\/td\u003e\n\u003ctd\u003e120m doses; €450m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Chronic Immunological Conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment covers patients with asthma, atopic dermatitis, and other chronic inflammatory diseases needing long‑term biologics; they seek high‑efficacy therapies that deliver durable remission and better daily functioning. In 2024 Sanofi's immunology portfolio-led by dupilumab-drove a ~12% revenue CAGR since 2021 and made immunology the company's fastest‑growing area, representing roughly $8.5B of sales in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Pediatric and Adult Vaccine Recipients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment covers global pediatric and adult vaccine recipients-about 140 million annual births (UN 2024) plus 1.2 billion adults targeted for seasonal influenza and booster programs-creating stable recurring demand for Sanofi's vaccines, which reported €6.5 billion in vaccines sales in 2024. Sanofi reaches them via national immunization schedules, tenders, and public-health campaigns, supplying WHO Gavi-supported programs and large procurement contracts with EU countries and the US CDC.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndividuals with Rare Genetic Disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThis niche but critical segment includes patients with Pompe and Gaucher diseases who need enzyme replacement therapies (ERTs); global rare disease prevalence is ~3.5-5.9% of the population, but Pompe affects ~1 in 40,000 and Gaucher ~1 in 40,000-60,000, so Sanofi targets high-value, lifelong care-these therapies can cost \u0026gt;$200,000 per patient annually, driving strategic focus on small cohorts with life-saving impact.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Professionals and Medical Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhysicians and specialists drive prescribing decisions for Sanofi's therapies; in 2024, clinicians accounted for over 70% of prescription volume for specialty drugs in Sanofi's key markets, making clinician adoption critical.\u003c\/p\u003e\n\u003cp\u003eThey require peer-reviewed clinical trials, real-world evidence, and timely medical-science liaison (MSL) support; for example, 92% of oncologists cite phase III data as decisive, and Sanofi allocates ~€1.5B yearly to R\u0026amp;D and medical affairs to build that conviction.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinician-driven prescribing \u0026gt;70% of specialty Rx volume\u003c\/li\u003e\n\u003cli\u003e92% of specialists rely on phase III data\u003c\/li\u003e\n\u003cli\u003eSanofi medical\/R\u0026amp;D spend ~€1.5B annually (2024)\u003c\/li\u003e\n\u003cli\u003eMSLs and real-world evidence key to uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernmental Health Agencies and Private Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernmental health agencies and private payers manage procurement and reimbursement for medicines, prioritizing cost-effectiveness, safety, and population health; in 2024 public payers covered ~60% of global drug spending and Germany, France, and the US set national access rules driving Sanofi pricing strategy.\u003c\/p\u003e\n\u003cp\u003eSecuring favorable HTA (health technology assessment) outcomes and negotiated prices-e.g., volume-based rebates or indication-based pricing that can affect revenue by 5-20%-is essential to ensure patient affordability and market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic payers ~60% of global drug spend (2024)\u003c\/li\u003e\n\u003cli\u003eHTA decisions alter revenue 5-20%\u003c\/li\u003e\n\u003cli\u003eFocus: cost-effectiveness, safety, population impact\u003c\/li\u003e\n\u003cli\u003eAccess tools: rebates, managed entry agreements, indication pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-value biologics, vaccines \u0026amp; rare therapies: payers and clinicians shaping $15B+ markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients needing biologics (asthma\/derm; immunology sales ≈ $8.5B in 2024), vaccine recipients (≈140M births + 1.2B adults; vaccines €6.5B in 2024), rare-disease patients (Pompe\/Gaucher; therapies \u0026gt;$200k\/yr), clinicians (drive \u0026gt;70% specialty Rx; 92% cite phase III), and payers (public ≈60% of drug spend; HTA shifts revenue 5-20%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 key metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmunology\u003c\/td\u003e\n\u003ctd\u003e$8.5B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccines\u003c\/td\u003e\n\u003ctd\u003e€6.5B sales; 140M births\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare disease\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$200k\/pt\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003e60% public spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntensive Research and Development Expenditure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi directs a large share of its budget to high-risk, high-reward R\u0026amp;D-covering lab research, preclinical work, and costly multi-phase trials; in 2024 Sanofi spent €6.8bn on R\u0026amp;D (≈15% of sales) and in 2025 is shifting more spend to immunology and mRNA programs, allocating roughly 20-25% of its R\u0026amp;D pipeline budget to those high-growth areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex Biological Manufacturing Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProducing biologics and vaccines costs far more than small-molecule drugs because of living cell culture, aseptic processing, and single-use\/bioreactor capital; Sanofi reported in 2024 R\u0026amp;D and manufacturing capex of about €2.1 billion, reflecting high setup and validation expenses. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi spends heavily on global sales and marketing-about €5.8 billion in 2024 (marketing \u0026amp; commercial costs within SG\u0026amp;A), funding a large field force and major launch campaigns to educate clinicians and win share in crowded therapeutic areas; spend on digital channels and analytics rose to ~18% of marketing in 2024 to boost targeting and ROI.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanofi spends heavily on compliance: global safety systems, facility audits, pharmacovigilance and regulatory filings-2024 R\u0026amp;D \u0026amp; SG\u0026amp;A drove about €12.5B of operating costs, with compliance-related inspections and legal filings representing a multi-hundred-million euro line annually.\u003c\/p\u003e\n\u003cp\u003eNon-compliance risks fines and recalls; 2023 EU\/US pharma penalties averaged €150-400M per major recall, so sustained investment in QA is non-negotiable.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual compliance spend: several hundred million €\u003c\/li\u003e\n\u003cli\u003eCompany-wide operating costs (2024): ~€12.5B\u003c\/li\u003e\n\u003cli\u003eTypical major recall penalty: €150-400M (2023 data)\u003c\/li\u003e\n\u003cli\u003eKey cost drivers: inspections, pharmacovigilance, legal filings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Transformation and IT Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanofi has increased IT and digital R\u0026amp;D spending, committing about €1.2bn in 2024 to digitalization and AI initiatives to speed data-driven drug discovery and automated manufacturing, and to modernize legacy systems.\u003c\/p\u003e\n\u003cp\u003eThese investments target higher operational efficiency and faster innovation cycles while strengthening cybersecurity to protect clinical and manufacturing data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 digital\/AI budget ≈ €1.2bn\u003c\/li\u003e\n\u003cli\u003eGoal: shorten discovery timelines, raise throughput\u003c\/li\u003e\n\u003cli\u003eFocus: legacy software modernization, cloud, cybersecurity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi 2024 Spend Breakdown: R\u0026amp;D, Commercial, Capex, Digital \u0026amp; Compliance Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi's cost base centers on R\u0026amp;D (€6.8bn in 2024, 15% of sales; 2025 shift: 20-25% pipeline focus on immunology\/mRNA), manufacturing capex (~€2.1bn 2024), commercial spend (€5.8bn 2024), compliance (several hundred million €\/yr) and digital\/AI (€1.2bn 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 (€bn)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e6.8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing capex\u003c\/td\u003e\n\u003ctd\u003e2.1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003e5.8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\/AI\u003c\/td\u003e\n\u003ctd\u003e1.2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003e0.3-0.6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Blockbuster Specialty Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSales of blockbuster specialty medicines like Dupixent drive Sanofi's revenue: Dupixent sales reached €9.4 billion in 2024 and helped specialty care become the main growth engine, contributing roughly 60% of group growth by 2025. These drugs carry premium pricing due to clear clinical benefits and high unmet need, sustaining strong margin and cash generation for R\u0026amp;D and market expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Vaccine Portfolio Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi's global vaccine portfolio yields stable, high-margin revenue-2024 vaccine sales reached €6.1bn, led by influenza and pediatric combination shots-driven by long-term government contracts and predictable seasonal demand. New launches such as the 2023 RSV vaccine helped diversify sales, contributing to ~€0.7bn incremental revenue in 2024 and lowering concentration risk across markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalties and Licensing Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi earns recurring, high-margin revenue from royalties and licensing-eg, the 2024 collaboration with Regeneron generated milestone receipts and tiered double-digit royalties on global sales of Libtayo and other co-developed assets, contributing to Sanofi's 2024 other income line of roughly €1.2 billion. These deals shift direct manufacturing risk to partners while preserving upside via milestone payments for clinical success and percentage-based royalties.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy General Medicine Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSanofi still earns significant cash from legacy general-medicine sales-diabetes and cardiovascular drugs generated about €4.1 billion in 2024, providing stable margins despite some generic erosion.\u003c\/p\u003e\n\u003cp\u003eThese established brands keep market share in many countries and fund R\u0026amp;D for new biologics and specialty medicines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€4.1bn legacy revenue (2024)\u003c\/li\u003e\n\u003cli\u003eHigh brand recognition, sustained demand\u003c\/li\u003e\n\u003cli\u003eBuffers R\u0026amp;D spend, offsets pipeline timing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing and Technical Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSanofi earns service revenue by contract manufacturing and technical services, using excess capacity to produce biologics and vaccines for third parties; in 2024 Sanofi's Vaccines \u0026amp; Rare Diseases manufacturing footprint helped lift group manufacturing utilization and contributed roughly €1.1-1.3bn in external revenue (estimate based on 2024 COGS mix and disclosed contract deals).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses excess biologics\/vaccine capacity\u003c\/li\u003e\n\u003cli\u003eGenerates ~€1.1-1.3bn external revenue (2024 estimate)\u003c\/li\u003e\n\u003cli\u003eImproves facility utilization and margins\u003c\/li\u003e\n\u003cli\u003eDiversifies beyond product sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi 2024: Dupixent-led specialty growth (€9.4bn) fuels high-margin R\u0026amp;D cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi's 2024 revenue mix: Dupixent €9.4bn; vaccines €6.1bn; legacy meds €4.1bn; royalties\/other income ~€1.2bn; external contract manufacturing €1.2bn (estimate), driving high-margin specialty growth and steady cash for R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 (€bn)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDupixent\/specialty\u003c\/td\u003e\n\u003ctd\u003e9.4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccines\u003c\/td\u003e\n\u003ctd\u003e6.1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy meds\u003c\/td\u003e\n\u003ctd\u003e4.1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\/other\u003c\/td\u003e\n\u003ctd\u003e1.2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract mfg (est.)\u003c\/td\u003e\n\u003ctd\u003e1.2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347635118411,"sku":"sanofi-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/sanofi-canvas-business-model.webp?v=1779158354","url":"https:\/\/valuechainanalysis.com\/products\/sanofi-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}